Saturday 17 October 2026
Export OCUL’s income statement to Excel — free account
Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 10.3%, free cash flow fell 25.4% and total debt rose 4.13%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.87
0.51
−6.91%
Follow OCUL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 2 | 5 | 2 | 6 | 4 | 3 | 3 | 4 | 4 |
P/S ratio |
109.42 | 72.08 | 76.23 | 42.31 | 72.26 | 12.23 | 4.17 | 6.57 | 21.21 | 43.75 |
Altman Z-Score |
1.29 | (6.37) | (5.12) | (8.33) | 1.46 | (1.07) | (5.25) | (2.45) | 2.91 | 6.91 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.68) | (16.98) | (13.47) | (19.24) | (2.40) | (5.17) | (12.37) | (5.49) | (0.82) | 3.49 |
Beneish M-Score |
1.01 | (3.78) | (2.39) | 2.80 | (1.60) | (0.12) | (2.50) | (2.61) | (3.01) | (2.92) |
P/Operating CF |
(27.12) | (13.35) | (11.11) | (9.19) | (201.34) | (35.14) | (12.65) | (17.10) | (34.28) | (41.90) |
P/B ratio |
3.97 | 5.30 | 4.23 | 0.00 | 16.53 | 6.05 | 6.06 | 4.21 | 4.29 | 3.47 |
Price to Tangible BV |
3.97 | 5.30 | 4.23 | 0.00 | 16.53 | 6.05 | 6.06 | 4.21 | 4.29 | 3.47 |
EV/Sales |
80.77 | 56.97 | 61.52 | 41.09 | 61.53 | 9.64 | 3.23 | 4.50 | 16.13 | 30.94 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.48) | (2.17) | (2.49) | (2.24) | (19.99) | (6.40) | (2.79) | (3.74) | (7.63) | (7.85) |
EV/FCF |
(4.24) | (1.87) | (2.39) | (2.18) | (19.68) | (6.29) | (2.62) | (3.45) | (7.56) | (7.42) |
Quick Ratio |
8.24 | 3.11 | 5.92 | 4.74 | 9.01 | 7.04 | 3.94 | 6.37 | 10.26 | 15.11 |
Current Ratio |
8.42 | 3.23 | 6.14 | 5.00 | 9.23 | 7.26 | 4.13 | 6.66 | 10.66 | 15.39 |
Net Debt/EBITDA |
1.28 | 0.48 | 0.52 | 0.06 | 3.11 | 1.49 | 0.63 | 1.52 | 1.93 | 2.51 |
Debt/Assets |
18.81% | 22.50% | 33.94% | 62.63% | 15.75% | 25.10% | 36.18% | 29.73% | 14.96% | 8.83% |
Debt/Equity |
0.27 | 0.48 | 0.69 | (13.58) | 0.54 | 0.58 | 1.53 | 0.82 | 0.22 | 0.11 |
Asset Turnover |
0.02 | 0.03 | 0.03 | 0.06 | 0.10 | 0.19 | 0.29 | 0.29 | 0.18 | 0.08 |
Operating CF/Net income |
0.76 | 0.80 | 0.82 | 0.90 | 0.34 | 10.00 | 0.84 | 0.87 | 0.70 | 0.77 |
Capex/Depreciation |
(1.80) | (5.02) | (0.83) | (0.88) | (0.30) | (0.49) | (1.76) | (2.04) | (0.34) | (2.75) |
Interest Coverage |
(25.79) | (32.73) | (34.00) | (14.06) | (9.29) | (11.70) | (11.20) | (7.27) | (12.65) | (22.82) |
| (63.14%) | (162.21%) | (193.41%) | (535.72%) | (429.55%) | (7.99%) | (115.16%) | (127.64%) | (95.21%) | (54.85%) | |
| (48.26%) | (97.24%) | (93.37%) | (113.81%) | (91.39%) | (2.81%) | (40.11%) | (40.23%) | (54.51%) | (42.01%) | |
ROIC |
0.00% | 0.00% | (559.74%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(68.87%) | (156.93%) | (104.73%) | (148.17%) | (68.38%) | (3.81%) | (65.72%) | (38.62%) | (47.31%) | (35.41%) |
Average Days of Receivables |
48.36 | 42.90 | 36.87 | 220.02 | 256.97 | 177.25 | 151.16 | 163.50 | 185.52 | 215.34 |
Research and Development Expense of Revenue |
1,434.29% | 1,605.82% | 1,855.03% | 972.11% | 164.88% | 115.08% | 103.82% | 104.47% | 200.30% | 379.39% |
Selling, General and Administrative Expense of Revenue |
938.26% | 1,690.54% | 1,192.36% | 1,102.74% | 284.28% | 154.11% | 140.11% | 127.46% | 160.45% | 227.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
315.63% | 380.71% | 376.03% | 207.22% | 43.27% | 34.41% | 32.94% | 30.50% | 51.96% | 83.12% |
Graham Net Nets |
0.23 | 0.10 | 0.13 | (0.12) | 0.05 | 0.14 | 0.07 | 0.19 | 0.22 | 0.28 |
Graham Number |
0.00 | 0.00 | 0.00 | 1.86 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(21.75%) | (45.74%) | (39.45%) | (48.35%) | (11.84%) | (1.29%) | (32.62%) | (20.93%) | (14.75%) | (11.86%) |
Free Cash Flow Yield |
(17.40%) | (42.36%) | (33.70%) | (44.63%) | (4.33%) | (12.54%) | (29.52%) | (19.88%) | (10.06%) | (9.54%) |
Revenue per Share |
0.08 | 0.07 | 0.05 | 0.09 | 0.29 | 0.57 | 0.67 | 0.73 | 0.40 | 0.28 |
Operating CF per Share |
(1.37) | (1.75) | (1.29) | (1.71) | (0.88) | (0.86) | (0.78) | (0.88) | (0.85) | (1.09) |
Capex per Share |
(0.08) | (0.29) | (0.05) | (0.05) | (0.01) | (0.02) | (0.05) | (0.08) | (0.01) | (0.06) |
Free Cash Flow per Share |
(1.45) | (2.04) | (1.34) | (1.76) | (0.90) | (0.87) | (0.82) | (0.96) | (0.86) | (1.16) |
Cash per Share |
2.75 | 1.44 | 1.42 | 1.20 | 3.75 | 2.15 | 1.33 | 2.45 | 2.48 | 3.94 |
Shareholders Equity per Share |
2.10 | 0.91 | 0.94 | (0.08) | 1.25 | 1.15 | 0.46 | 1.14 | 1.99 | 3.49 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.10 | 0.91 | 0.94 | (0.08) | 1.25 | 1.15 | 0.46 | 1.14 | 1.99 | 3.49 |
Free Cash Flow |
(35.92) | (58.72) | (51.12) | (79.82) | (54.39) | (66.74) | (63.32) | (76.32) | (135.96) | (216.76) |
Working Capital |
61.60 | 29.91 | 47.03 | 48.14 | 219.50 | 164.96 | 98.23 | 197.34 | 399.63 | 731.32 |
Capital Expenditures |
(1.92) | (8.25) | (1.89) | (2.24) | (0.84) | (1.19) | (3.71) | (6.09) | (1.29) | (11.88) |
Net Current Asset Value |
46.97 | 14.06 | 19.03 | (22.20) | 60.39 | 74.41 | 15.72 | 71.31 | 298.40 | 628.38 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.02 | 4.29 | 0.95 | 0.53 | 0.05 | 0.03 | 0.07 | 0.10 | 0.02 | 0.23 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.32 | 0.16 | 0.22 | 0.25 | 0.34 | 0.35 | 0.21 | 0.25 | 0.40 | 0.22 |
Cash ROIC |
(26.76%) | (73.26%) | (44.56%) | (79.72%) | (15.75%) | (21.98%) | (33.03%) | (21.08%) | (17.52%) | (14.82%) |
Accounts Receivable Turnover |
8.52 | 8.08 | 9.32 | 3.08 | 2.35 | 2.61 | 2.43 | 2.46 | 2.18 | 1.65 |
Accounts Payable Turnover |
0.22 | 0.16 | 0.14 | 0.75 | 0.70 | 1.21 | 0.93 | 1.11 | 1.31 | 1.58 |
Inventory Turnover |
3.59 | 3.89 | 2.74 | 3.97 | 1.93 | 3.60 | 2.82 | 2.47 | 2.11 | 1.99 |
Average Days of Payables |
1,743.43 | 2,852.11 | 2,327.37 | 513.04 | 474.69 | 380.41 | 411.87 | 303.35 | 270.93 | 230.64 |
Days of Inventory on Hand |
93.10 | 97.44 | 170.33 | 149.77 | 210.45 | 103.55 | 158.70 | 159.31 | 197.23 | 197.88 |
Average Receivables |
0.22 | 0.24 | 0.21 | 1.37 | 7.40 | 16.69 | 21.23 | 23.75 | 29.28 | 31.52 |
Average Payables |
2.04 | 2.84 | 3.27 | 3.12 | 2.99 | 3.65 | 4.86 | 4.76 | 4.28 | 4.17 |
Average Inventory |
0.12 | 0.12 | 0.17 | 0.59 | 1.08 | 1.23 | 1.61 | 2.14 | 2.67 | 3.30 |
Average Assets |
92.62 | 65.19 | 64.24 | 75.89 | 170.30 | 233.38 | 177.09 | 200.67 | 355.00 | 633.00 |
Average Common Equity |
70.80 | 39.08 | 31.01 | 16.12 | 36.23 | 82.05 | 61.69 | 63.26 | 203.24 | 484.83 |
Columns are period end dates